Abstract
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have